Global Transthyretin Amyloidosis (ATTR) Market Size By Type (Hereditary ATTR (HATTR), Wild-Type (WT) ATTR), By Application (Hospitals, Ambulatory Surgical Centers), By Region, And Segment Forecasts, 2...

lobal Transthyretin Amyloidosis (ATTR) Market Report

The Global Transthyretin Amyloidosis (ATTR) Market was valued at USD 4.1 billion in 2023 and is projected to surpass USD 10.6 billion by 2031, registering a CAGR of 12.4% during the forecast period (2023–2031). ATTR amyloidosis is a rare and progressive condition caused by the misfolding of transthyretin protein, leading to amyloid deposits in tissues and organs. The increasing awareness of rare diseases, advancements in diagnostic technologies, and the approval of novel therapeutics such as RNAi therapies and TTR stabilizers are driving significant market growth.

The expanding patient pool due to improved diagnostic rates, coupled with favorable reimbursement policies in developed countries, further supports the ATTR market expansion.

Drivers

1. Rising Awareness and Improved Diagnostics

Growing awareness of transthyretin amyloidosis among healthcare professionals and patients is leading to early diagnosis. Innovations in imaging technologies and genetic testing are enabling precise disease detection, boosting treatment uptake.

2. Emergence of Disease-Modifying Therapies

The approval of therapies such as tafamidis, patisiran, and vutrisiran has transformed the ATTR treatment landscape. These disease-modifying therapies slow disease progression and improve survival, creating strong demand.

3. Supportive Regulatory and Reimbursement Frameworks

Government and non-government initiatives to support rare disease treatment, including orphan drug designations and reimbursement support, are encouraging pharmaceutical companies to invest in ATTR therapeutics.

Restraints

1. High Treatment Costs

ATTR therapies are extremely expensive, limiting access for patients in low- and middle-income countries. The high cost of lifelong treatment remains a major barrier to widespread adoption.

2. Limited Awareness in Developing Regions

In several emerging economies, awareness and diagnosis of ATTR remain low, restricting the potential market expansion outside North America and Europe.

Opportunity

1. Expansion into Emerging Markets

With rising healthcare expenditure in Asia-Pacific and Latin America, these regions present untapped opportunities for ATTR therapeutics. Strategic partnerships with local healthcare providers could drive accessibility.

2. Development of Next-Generation RNAi and Gene Therapies

Advancements in gene-editing technologies and RNA interference therapies offer new opportunities for developing more effective and potentially curative treatments for ATTR amyloidosis.

Market by Treatment Type Insights

Based on treatment type, TTR stabilizers (e.g., tafamidis) accounted for the largest market share in 2023 due to their established efficacy and regulatory approvals. However, RNAi-based therapies (e.g., patisiran, vutrisiran) are expected to witness the highest growth rate owing to their disease-modifying potential and expanded clinical indications.

Market by End-Use Insights

Hospitals and specialized amyloidosis centers represented the largest end-use segment in 2023, driven by the complexity of disease management and the need for advanced diagnostic tools. The specialty pharmacy distribution channel is also growing rapidly due to the high-cost nature of these therapies.

Market by Regional Insights

North America dominated the ATTR market in 2023, supported by high diagnosis rates, advanced healthcare infrastructure, and the presence of key pharmaceutical companies.

Europe followed closely, with significant uptake of tafamidis and other approved therapies due to favorable reimbursement policies.

Asia-Pacific is projected to experience the fastest growth during the forecast period, fueled by increasing awareness, better diagnostic capabilities, and expanding access to novel therapeutics in countries like Japan and South Korea.

Competitive Scenario

The ATTR market is highly competitive, with key players focusing on expanding indications, developing next-generation therapies, and strategic collaborations. Major companies include:

Pfizer Inc. (tafamidis – Vyndaqel)

Alnylam Pharmaceuticals (patisiran – Onpattro, vutrisiran – Amvuttra)

Ionis Pharmaceuticals (inotersen – Tegsedi)

Eidos Therapeutics (acoramidis)

BridgeBio Pharma

Recent developments include:

2024: Alnylam received regulatory approval for vutrisiran in new geographies, expanding its ATTR polyneuropathy treatment footprint.

2023: Eidos Therapeutics announced positive Phase 3 results for acoramidis, a next-generation TTR stabilizer expected to challenge tafamidis.

2023: Pfizer launched expanded access programs in Asia-Pacific to improve patient reach for tafamidis.

Scope of Work – Global Transthyretin Amyloidosis (ATTR) Market

Key Market Developments

March 2024: Alnylam Pharmaceuticals launched vutrisiran in key European markets for ATTR amyloidosis with cardiomyopathy.

October 2023: Pfizer expanded its tafamidis label to include ATTR cardiomyopathy with earlier-stage disease, broadening the eligible patient pool.

July 2023: BridgeBio Pharma initiated Phase 3 trials for a gene-editing therapy aimed at achieving a one-time curative treatment for ATTR.

FAQs

1. What is the current market size of the Global Transthyretin Amyloidosis (ATTR) Market?

The market was valued at USD 4.1 billion in 2023.

2. What is the major growth driver of the Global Transthyretin Amyloidosis (ATTR) Market?

The key driver is the approval and uptake of disease-modifying therapies, coupled with improved diagnostic rates.

3. Which is the largest region during the forecast period in the Global Transthyretin Amyloidosis (ATTR) Market?

North America is expected to remain the largest region due to high awareness, advanced healthcare infrastructure, and strong presence of key players.

4. Which segment accounted for the largest market share in the Global Transthyretin Amyloidosis (ATTR) Market?

TTR stabilizers accounted for the largest market share in 2023.

5. Who are the key market players in the Global Transthyretin Amyloidosis (ATTR) Market?

Key players include Pfizer, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Eidos Therapeutics, and BridgeBio Pharma.

Would you like me to also generate a downloadable DOCX report in this exact structured format for ATTR market?